Clinical Trials Register

Summary
EudraCT Number:	2022-000719-30
Sponsor's Protocol Code Number:	GLPG0634-CL-341
National Competent Authority:	Spain - AEMPS
Clinical Trial Type:	EEA CTA
Trial Status:	Prematurely Ended
Date on which this record was first entered in the EudraCT database:	2022-08-03
Trial results

Index
A. PROTOCOL INFORMATION
B. SPONSOR INFORMATION
C. APPLICANT IDENTIFICATION
D. IMP IDENTIFICATION
D.8 INFORMATION ON PLACEBO
E. GENERAL INFORMATION ON THE TRIAL
F. POPULATION OF TRIAL SUBJECTS
G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
P. END OF TRIAL

Expand All Collapse All

A. Protocol Information

A.1

Member State Concerned

Spain - AEMPS

A.2

EudraCT number

2022-000719-30

A.3

Full title of the trial

A randomized, double-blind, controlled, multi-center study to evaluate the efficacy and safety of dose de-escalation of orally administered filgotinib in subjects with ulcerative colitis in clinical remission

Estudio aleatorizado, doble ciego, controlado y multicéntrico para evaluar la eficacia y la seguridad de la reducción progresiva de la dosis de filgotinib administrado por vía oral en pacientes con colitis ulcerosa en remisión clínica

A.3.1

Title of the trial for lay people, in easily understood, i.e. non-technical, language

A study evaluating the effect of filgotinib dose de-escalation in patients with ulcerative colitis in remission

Estudio para evaluar el efecto de la reducción progresiva de la dosis de filgotinib en pacientes con colitis ulcerosa en remisión

A.4.1

Sponsor's protocol code number

GLPG0634-CL-341

A.7

Trial is part of a Paediatric Investigation Plan

A.8

EMA Decision number of Paediatric Investigation Plan

B. Sponsor Information
B.Sponsor: 1
B.1.1	Name of Sponsor	Galapagos NV
B.1.3.4	Country	Belgium
B.3.1 and B.3.2	Status of the sponsor	Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1	Name of organisation providing support	Galapagos NV
B.4.2	Country	Belgium
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1	Name of organisation	Galapagos NV
B.5.2	Functional name of contact point	Galapagos Medical Information
B.5.3	Address:
B.5.3.1	Street Address	Generaal de Wittelaan L11 A3
B.5.3.2	Town/ city	Mechelen
B.5.3.3	Post code	2800
B.5.3.4	Country	Belgium
B.5.6	E-mail	medicalinfo@glpg.com

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3	IMP Role	Test
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	Yes
D.2.1.1.1	Trade name	Jyseleca
D.2.1.1.2	Name of the Marketing Authorisation holder	Galapagos NV
D.2.1.2	Country which granted the Marketing Authorisation	European Union
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	No
D.2.5.1	Orphan drug designation number
D.3 Description of the IMP
D.3.1	Product name	Filgotinib
D.3.2	Product code	GLPG0634
D.3.4	Pharmaceutical form	Film-coated tablet
D.3.4.1	Specific paediatric formulation	No
D.3.7	Routes of administration for this IMP	Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	Filgotinib
D.3.9.2	Current sponsor code	GLPG0634
D.3.9.3	Other descriptive name	Jyseleca
D.3.9.4	EV Substance Code	SUB182273
D.3.10	Strength
D.3.10.1	Concentration unit	mg milligram(s)
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	100
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	Yes
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	No
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	No
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	No
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No
D.IMP: 2
D.1.2 and D.1.3	IMP Role	Test
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	Yes
D.2.1.1.1	Trade name	Jyseleca
D.2.1.1.2	Name of the Marketing Authorisation holder	Galapagos NV
D.2.1.2	Country which granted the Marketing Authorisation	European Union
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	No
D.2.5.1	Orphan drug designation number
D.3 Description of the IMP
D.3.1	Product name	Filgotinib
D.3.2	Product code	GLPG0634
D.3.4	Pharmaceutical form	Film-coated tablet
D.3.4.1	Specific paediatric formulation	No
D.3.7	Routes of administration for this IMP	Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	Filgotinib
D.3.9.2	Current sponsor code	GLPG0634
D.3.9.3	Other descriptive name	Jyseleca
D.3.9.4	EV Substance Code	SUB182273
D.3.10	Strength
D.3.10.1	Concentration unit	mg milligram(s)
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	200
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	Yes
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	No
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	No
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	No
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No

D.8 Information on Placebo
D.8 Placebo: 1
D.8.1	Is a Placebo used in this Trial?	Yes
D.8.3	Pharmaceutical form of the placebo	Film-coated tablet
D.8.4	Route of administration of the placebo	Oral use
D.8 Placebo: 2
D.8.1	Is a Placebo used in this Trial?	Yes
D.8.3	Pharmaceutical form of the placebo	Film-coated tablet
D.8.4	Route of administration of the placebo	Oral use

E. General Information on the Trial

E.1 Medical condition or disease under investigation

E.1.1

Medical condition(s) being investigated

ulcerative colitis (UC)

colitis ulcerosa

E.1.1.1

Medical condition in easily understood language

ulcerative colitis

colitis ulcerosa

E.1.1.2

Therapeutic area

Diseases [C] - Digestive System Diseases [C06]

MedDRA Classification

E.1.2 Medical condition or disease under investigation

E.1.2	Version	20.1
E.1.2	Level	LLT
E.1.2	Classification code	10045365
E.1.2	Term	Ulcerative colitis
E.1.2	System Organ Class	100000004856

E.1.3

Condition being studied is a rare disease

E.2 Objective of the trial

E.2.1

Main objective of the trial

To evaluate the efficacy of filgotinib in subjects in stable clinical remission on 200 mg filgotinib once daily (q.d.) for whom the dose was decreased to 100 mg q.d. compared to subjects remaining on 200 mg q.d.

Evaluar la eficacia de filgotinib en pacientes en remisión clínica estable con 200 mg de filgotinib una vez al día (1 v/d) para los que se redujo la dosis a 100 mg 1 v/d en comparación con los pacientes que siguen recibiendo 200 mg 1 v/d.

E.2.2

Secondary objectives of the trial

- To evaluate the effect of dose de-escalation of filgotinib on time to flare.
- To evaluate the effect of dose de-escalation of filgotinib on disease-specific biomarkers and Inflammatory Bowel Disease Questionnaire.
- To evaluate the safety and tolerability of filgotinib.

- Evaluar el efecto de la reducción progresiva de la dosis de filgotinib en el tiempo hasta la exacerbación
- Evaluar el efecto de la reducción progresiva de la dosis de filgotinib sobre los biomarcadores específicos de la enfermedad y el Cuestionario de la enfermedad inflamatoria intestinal (Inflammatory Bowel Disease Questionnaire, IBDQ)
- Evaluar la seguridad y tolerabilidad de filgotinib

E.2.3

Trial contains a sub-study

Yes

E.2.3.1

Full title, date and version of each sub-study and their related objectives

PK substudy

Sub-estudio de FC

E.3

Principal inclusion criteria

− Subjects must be participating in the SELECTION-LTE study, currently on 200 mg filgotinib q.d. and fulfill the following conditions:
• pMCS remission over a period of at least 2 consecutive quarterly visits in the SELECTION-LTE study prior to and including screening of the present study;
• free of corticosteroids for at least 12 weeks prior to and including baseline;
• FCP <=250 μg/g at last observation;
• sigmoidoscopy ES of 0 or 1 (local score) at screening.
− Female subjects of childbearing potential must have a negative highly sensitive (serum beta human chorionic gonadotropin) pregnancy test during screening and must agree to continued monthly urine dipstick pregnancy testing during filgotinib treatment.
− Male subjects and female subjects of childbearing potential must agree to use highly effective contraception measures as defined in the protocol.
− Willing to refrain from live attenuated vaccines during the study and for 12 weeks after the last dose of filgotinib in the study.

This list only contains the key inclusion criteria.

- Los pacientes deben participar en el estudio SELECTION-LTE, estar recibiendo actualmente tratamiento con 200 mg de filgotinib 1 v/d y cumplir las siguientes condiciones:
•remisión de la pMCS durante un período de al menos 2 visitas trimestrales consecutivas en el estudio SELECTION-LTE antes de y en la propia selección del presente estudio;
•sin corticoesteroides durante al menos 12 semanas antes del inicio (inclusive);
•CPF <= 250 μg/g en la última observación;
•PE de la sigmoidoscopia de 0 o 1 (puntuación local) en la selección.
- Las pacientes con capacidad de concebir deben tener un resultado negativo en una prueba de embarazo altamente sensible (gonadotropina coriónica humana beta en suero) durante la selección y deben aceptar someterse mensualmente a una prueba de embarazo con tira reactiva de orina durante el tratamiento con filgotinib.
- Los pacientes de sexo masculino y las pacientes de sexo femenino con capacidad de concebir deben aceptar el uso de métodos anticonceptivos altamente eficaces, tal y como se define en el protocolo.
- Disposición para evitar recibir vacunas elaboradas con microorganismos vivos atenuados durante el estudio y durante 12 semanas tras la última dosis de filgotinib en el estudio.

Esta lista sólo contiene los principales criterios de inclusión.

E.4

Principal exclusion criteria

− Any chronic medical condition (including but not limited to, cardiac or pulmonary disease, alcohol, or drug abuse) that, in the opinion of the investigator or sponsor, would make the subject unsuitable for the study or would prevent compliance with the study protocol.
− Subject has a known hypersensitivity to filgotinib ingredients or history of a significant allergic reaction to filgotinib ingredients as determined by the investigator.
− Female subject who is pregnant or breastfeeding, or intending to become pregnant or breastfeed, and/or plans to undergo egg donation or egg harvesting for the purpose of current or future fertilization, during the study and until the end of the study.
− Male subject unwilling to refrain from sperm donation for at least 90 days after the last dose of investigational product.
− Subject is unable or unwilling to comply with restrictions regarding prior and concomitant medication as described in the protocol.
− Subject has a positive QuantiFERON® tuberculosis (TB) test at screening or subject has 2 indeterminate QuantiFERON® TB test results who require IP treatment interruption.
− History of malignancy except for subjects who have been successfully treated for nonmelanoma skin cancer or cervical carcinoma in situ.
− Subject meets discontinuation criteria of the SELECTION-LTE study.

This list only contains the key exclusion criteria.

- Cualquier afección médica crónica (entre otras, neumopatía o cardiopatía, alcoholismo o drogadicción) que, en opinión del investigador o el promotor, haga que el paciente no sea apto para el estudio o impida el cumplimiento del protocolo del mismo.
- El paciente tiene hipersensibilidad conocida a los ingredientes de filgotinib o antecedentes de una reacción alérgica significativa a los ingredientes de filgotinib según lo determinado por el investigador.
- Mujer embarazada o en período de lactancia, con intención de quedarse embarazada o de amamantar, y/o que tenga previsto someterse a una donación o extracción de óvulos con fines de fecundación actual o futura, durante el estudio y hasta el final del mismo.
- Hombres que no estén dispuestos a abstenerse de donar semen durante al menos 90 días después de la última dosis del producto en investigación (PEI).
- El paciente no puede o no está dispuesto a cumplir con las restricciones relativas a la medicación previa y concomitante, tal y como se describe en el protocolo.
- El paciente tiene un resultado positivo en la prueba de tuberculosis (TB) QuantiFERON® en la selección o 2 resultados indeterminados en la prueba de TB QuantiFERON® que requieren la interrupción del tratamiento con el PEI.
- Antecedentes de neoplasia maligna, excepto pacientes tratados satisfactoriamente para un cáncer de piel distinto del melanoma o un carcinoma cervicouterino in situ.
- El paciente cumple los criterios de interrupción del estudio SELECTION-LTE

Esta lista sólo contiene los principales criterios de exclusión.

E.5 End points

E.5.1

Primary end point(s)

Proportion of subjects in corticosteroid-free clinical remission based on modified Mayo Clinical Score.

Proporción de pacientes en remisión clínica sin corticoesteroides según la Puntuación de la Clínica Mayo modificada

E.5.1.1

Timepoint(s) of evaluation of this end point

Week 48

Semana 48

E.5.2

Secondary end point(s)

− Time to patient-reported outcome based on 2 items (PRO2) flare.
− Time to endoscopic score-confirmed ulcerative colitis flare.
− Change from baseline in C-reactive protein and fecal calprotectin.
− Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) .
− Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious Adverse Events (AEs), and TEAEs leading to treatment discontinuation.

- Tiempo hasta la exacerbación del resultado notificado por el paciente basado en 2 ítems (RNP2).
- Tiempo hasta la exacerbación de la colitis ulcerosa confirmada por la puntuación endoscópica.
- Variación con respecto al valor inicial en la proteína C reactiva y la calprotectina fecal.
- Variación con respecto al valor inicial en el Cuestionario de Enfermedad Inflamatoria Intestinal (CEII).
- Frecuencia e intensidad de los acontecimientos adversos surgidos durante el tratamiento (AAST), los acontecimientos adversos graves surgidos durante tratamiento (AA) y de los AAST que provocan la interrupción del tratamiento.

E.5.2.1

Timepoint(s) of evaluation of this end point

Various time points throughout the study as per clinical study design.

Varios puntos de tiempo a lo largo del estudio según el diseño del estudio clínico.

E.6 and E.7 Scope of the trial

E.6

Scope of the trial

E.6.1

Diagnosis

E.6.2

Prophylaxis

E.6.3

Therapy

E.6.4

Safety

Yes

E.6.5

Efficacy

Yes

E.6.6

Pharmacokinetic

Yes

E.6.7

Pharmacodynamic

E.6.8

Bioequivalence

E.6.9

Dose response

E.6.10

Pharmacogenetic

E.6.11

Pharmacogenomic

E.6.12

Pharmacoeconomic

E.6.13

Others

Yes

E.6.13.1

Other scope of the trial description

Biomarker assessments

Evaluaciones de biomarcadores

E.7

Trial type and phase

E.7.1

Human pharmacology (Phase I)

E.7.1.1

First administration to humans

E.7.1.2

Bioequivalence study

E.7.1.3

Other

E.7.1.3.1

Other trial type description

E.7.2

Therapeutic exploratory (Phase II)

E.7.3

Therapeutic confirmatory (Phase III)

Yes

E.7.4

Therapeutic use (Phase IV)

E.8 Design of the trial

E.8.1

Controlled

Yes

E.8.1.1

Randomised

Yes

E.8.1.2

Open

E.8.1.3

Single blind

E.8.1.4

Double blind

Yes

E.8.1.5

Parallel group

Yes

E.8.1.6

Cross over

E.8.1.7

Other

E.8.2

Comparator of controlled trial

E.8.2.1

Other medicinal product(s)

E.8.2.2

Placebo

Yes

E.8.2.3

Other

E.8.2.4

Number of treatment arms in the trial

E.8.3

The trial involves single site in the Member State concerned

E.8.4

The trial involves multiple sites in the Member State concerned

Yes

E.8.4.1

Number of sites anticipated in Member State concerned

E.8.5

The trial involves multiple Member States

Yes

E.8.5.1

Number of sites anticipated in the EEA

E.8.6 Trial involving sites outside the EEA

E.8.6.1

Trial being conducted both within and outside the EEA

Yes

E.8.6.2

Trial being conducted completely outside of the EEA

E.8.6.3

If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned

India

Korea, Republic of

South Africa

Taiwan

United States

France

Poland

Spain

Switzerland

Czechia

Germany

Italy

Belgium

Hungary

United Kingdom

E.8.7

Trial has a data monitoring committee

E.8.8

Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial

when the last subject is switched to commercially available filgotinib (i.e. after completing minimum 48 weeks of treatment and the follow-up visit) or, in countries where filgotinib is not commercially available, when the last subject completes 216 weeks in the study.

cuando el último sujeto se cambie a filgotinib comercialmente disponible (es decir, después de completar un mínimo de 48 semanas de tratamiento y la visita de seguimiento) o, en los países en los que filgotinib no está comercialmente disponible, cuando el último sujeto complete 216 semanas en el estudio.

E.8.9 Initial estimate of the duration of the trial

E.8.9.1

In the Member State concerned years

E.8.9.1

In the Member State concerned months

E.8.9.1

In the Member State concerned days

E.8.9.2

In all countries concerned by the trial years

E.8.9.2

In all countries concerned by the trial months

E.8.9.2

In all countries concerned by the trial days

F. Population of Trial Subjects

F.1 Age Range

F.1.1

Trial has subjects under 18

F.1.1.1

In Utero

F.1.1.2

Preterm newborn infants (up to gestational age < 37 weeks)

F.1.1.3

Newborns (0-27 days)

F.1.1.4

Infants and toddlers (28 days-23 months)

F.1.1.5

Children (2-11years)

F.1.1.6

Adolescents (12-17 years)

F.1.2

Adults (18-64 years)

Yes

F.1.2.1

Number of subjects for this age range:

F.1.3

Elderly (>=65 years)

Yes

F.1.3.1

Number of subjects for this age range:

F.2 Gender

F.2.1

Female

Yes

F.2.2

Male

Yes

F.3 Group of trial subjects

F.3.1

Healthy volunteers

F.3.2

Patients

Yes

F.3.3

Specific vulnerable populations

Yes

F.3.3.1

Women of childbearing potential not using contraception

F.3.3.2

Women of child-bearing potential using contraception

Yes

F.3.3.3

Pregnant women

F.3.3.4

Nursing women

F.3.3.5

Emergency situation

F.3.3.6

Subjects incapable of giving consent personally

F.3.3.7

Others

F.4 Planned number of subjects to be included

F.4.1

In the member state

F.4.2

For a multinational trial

F.4.2.1

In the EEA

F.4.2.2

In the whole clinical trial

F.5

Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)

None

Ninguno

G. Investigator Networks to be involved in the Trial

N. Review by the Competent Authority or Ethics Committee in the country concerned

Competent Authority Decision

Authorised

Date of Competent Authority Decision

2022-10-24

Ethics Committee Opinion of the trial application

Favourable

Ethics Committee Opinion: Reason(s) for unfavourable opinion

Date of Ethics Committee Opinion

2022-09-08

P. End of Trial
P.	End of Trial Status	Prematurely Ended

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials